BioMarin Pharmaceutical Inc. (BMRN) stock declined over -0.13% intraday to trade at $95.7 a share on NASDAQ. The stock opened with a gain of 4.13% at $96.21 and touched an intraday high of $97.76, falling -0.13% against the last close of $95.82. The stock went to a low of $93.93 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue1.88 Billion
5Y Sales Change10.6%
Fiscal Year Ends2021-12-30
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; BMN 307, an AAV5 mediated gene therapy, which is in phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; BMN 331 for the treatment of hereditary angioedema; BMN 255 for the treatment of chronic renal disease; and BMN 351 for the treatment of Duchenne Muscular Dystrophy. The company has collaboration and license agreements with Sarepta Therapeutics, Asubio Pharma Co., Ltd., and DiNAQOR AG. The company serves specialty pharmacies, hospitals, and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration with Allen Institute. BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) stock price is $95.7 as of the last check on Monday, August 8. During the trading session, BMRN stock reached the peak price of $97.76 while $93.93 was the lowest point it dropped to.
The NASDAQ listed BMRN is part of Biotechnology industry that operates in the broader Health Care sector. BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.
Ms. Andrea L. Acosta
Group VP & Chief Accounting Officer
Dr. Brinda Balakrishnan M.D., Ph.D.
Group VP of Corp. & Bus. Devel.
Mr. Jean-Jacques Bienaime M.B.A., MBA
Chairman & CEO
Mr. Brian R. Mueller
Exec. VP of Fin. & CFO
BMRN stock traded closed the last session at $95.7, which is -$0.11999999999999034 or -0.13% lower than its previous close of $95.82. BMRN's current trading price is 35.3% lower than its 52-week high of $96.5 where as its distance from 52-week low of 70.73% is -0.83%.
Number of BMRN employees currently stands at -. BMRN operates from 770 Lindaro Street, San Rafael, CA 94901, United States.
Official Webiste of $BMRN is: https://www.biomarin.com
BMRN stock volume for the day was 1,702,209 shares while in the previous session number of BMRN shares traded was 1,341,291 . The average number of BMRN shares traded daily for last 3 months was 1.19 Million.
The percentage change in BMRN stock occurred in the recent session was -0.13% while the dollar amount for the price change in BMRN stock was -$0.11999999999999034.
In the recent session, the day high for BMRN stock was $97.76 while the low for BMRN stock touched on the day was $93.93.
The market value of BMRN currently stands at 17.18 Billion with its latest stock price at $95.7 and 185.25 Million of its shares outstanding.